Gilead Sciences, Inc. (GILD): Revenue
$29.44B
Year ended 2025-12-31
$30.46B
Trailing 12 months to 2026-06-30
+2.6%
3-year compound annual growth
+3.6%
5-year compound annual growth
-1.0%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.44B | +2.4% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $28.75B | +6.0% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $27.12B | -0.6% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $27.28B | -0.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $27.30B | +10.6% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $24.69B | +10.0% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $22.45B | +1.5% | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $22.13B | -15.2% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $26.11B | -14.1% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $30.39B | -6.9% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $32.64B | +31.1% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $24.89B | +122.2% | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | $11.20B | +15.5% | 2016-02-24, From 2013-01-01 |
| 2012-12-31 | $9.70B | +15.7% | 2013-02-27, From 2012-01-01 |
| 2011-12-31 | $8.39B | +5.5% | 2013-02-27, From 2011-01-01 |
| 2010-12-31 | $7.95B | +13.4% | 2013-02-27, From 2010-01-01 |
| 2009-12-31 | $7.01B | +31.4% | 2012-02-23, From 2009-01-01 |
| 2008-12-31 | $5.34B | +26.1% | 2011-02-28, From 2008-01-01 |
| 2007-12-31 | $4.23B | n/a | 2010-03-01, From 2007-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $29.44B | +2.4% |
| Amgen Inc (AMGN) | 2025-12-31 | $36.75B | +10.0% |
| Biogen Inc. (BIIB) | 2025-12-31 | $9.89B | +2.2% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $2.86B | +21.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.32B | +7.0% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $2.09B | +5.7% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $1.94B | -39.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $1.40B | +37.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.22B | -0.4% |
Compare GILD, AMGN, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗